As cleaning validation expectations continue to evolve, Cretex Medical | QTS helps OEMs implement data-driven, risk-based validation strategies that support regulatory compliance, process consistency, and long-term product quality.
July 21, 2026
Learn how Cretex Medical | QTS helps manufacturers move beyond traditional cleaning validation with statistically robust, future-focused approaches that strengthen process capability and regulatory readiness.
The medical device industry has always been defined by its commitment to patient safety. However, the methods we use to ensure safety are constantly evolving. As we move through 2026, the expectations for cleaning validations have shifted from a simple "check the box" exercise to a complex, data-driven science. For medical device manufacturers, keeping up with these changes is not just about compliance; it is also about ensuring every device that reaches a patient is clean and safe for use.
Historically, cleaning and sterilization validations have been viewed independently. Today, we know that the two are inextricably linked. You cannot have a reliable sterilization process without a validated and consistent cleaning process. As regulatory bodies worldwide increase their scrutiny, original equipment manufacturers (OEMs) should consider more than just the minimum requirements and adopt strategies that are robust enough to handle the challenges of tomorrow.
At Cretex Medical | QTS, we do not just react to new standards. We help create them. With an understanding of core regulatory principles, we actively contribute to numerous regulatory publications, so we can help our customers future-proof their validation strategies.
One of the most significant changes in the cleaning validation landscape is the move toward statistical process capability analysis. Previously, in medical device cleaning process validation, it was common to test a small number of samples, compare them to a residue limit, and call the process validated if all data was below the specified residue limit. That approach is becoming obsolete.
Regulators now expect cleaning validation to be treated as a true process validation. This means you must demonstrate that your cleaning process is stable and capable of producing consistent results over time. Sample sizes with no significance may not adequately show that your process will remain effective during full-scale production.
To meet these modern expectations, manufacturers now must use valid statistical approaches to determine sample sizes. This often involves performing a one-sided capability analysis, such as calculating CpK (Process Capability Index) or PpK (Process Performance Index) values for variable data. By using these statistical tools, you can determine if your process provides enough buffer between your actual residue levels and your established limits.
If your data is stacked close to the limit or shows high variability, there is a high risk of failure during production. A robust validation must prove that the process is capable under natural variability, such as shift changes, temperature fluctuations, and load size. At Cretex Medical | QTS, we emphasize this statistical rigor from the start. We help our clients move away from the test-a-few-parts mentality toward using significant data to provide long-term confidence.
A common pitfall in cleaning validation is the over-reliance on targeted test methods. Total Organic Carbon (TOC) and Total Hydrocarbon (THC) testing are popular choices because they are specific and sensitive. They are excellent tools for identifying certain types of residues, particularly those tied to biocompatibility risks. However, relying solely on these methods can create a false sense of security.
Targeted tests only look for what they are designed to find. If a manufacturing process introduces a residue that does not contain organic carbon or hydrocarbons, a TOC or THC test will miss it entirely. This leaves a gap in your validation that could lead to loss of process control, regulatory findings, or worse, patient safety issues.
Furthermore, targeted tests often produce results that are "below the limit of detection" (LOD). While it might seem like a good thing to have zero detectable residue, data that is consistently below the LOD is difficult to analyze statistically. Process capability evaluation and trending are not of much value if your data points are all zero.
For these reasons, we often suggest a non-specific approach like gravimetric analysis. Gravimetric testing quantifies the total mass of all extracted materials, regardless of their composition. Because it captures everything, the results are much more likely to produce quantifiable, variable data. This allows for a meaningful evaluation of process capability. While the residue limits for gravimetric analysis might be higher than those for targeted tests, the data provided is a more accurate reflection of the overall cleanliness of the device.
Validation is not just about the final test. It is about the entire design and manufacturing sequence. One of the biggest mistakes an OEM can make is waiting until a design is frozen before thinking about how the device will be cleaned. Complex geometries, such as deep blind holes, lumens, and textured surfaces, can trap manufacturing residues and make them nearly impossible to remove.
Beyond design, the daily controls of the cleaning process are equally critical. Regulators are increasingly focused on process controls like bath life and fixture loading. If you have not established a limit for how many parts can be cleaned before the solution needs to be refreshed, your process is not truly validated. Similarly, if you have not defined how parts should be oriented in a fixture to ensure maximum exposure to cleaning and rinsing agents, you risk inconsistent results.
At Cretex Medical | QTS, we help OEMs establish these minimum process controls. We look at the manufacturing sequence as a whole, ensuring that every step, from the first machining operation to the final packaging, is designed to support a clean and sterile end product.
The regulatory environment is not static. Standards like ISO 19227 are currently under revision, and we expect requirements to evolve in light of new technologies and new thinking. This is where a partnership with Cretex Medical | QTS becomes a strategic advantage.
Our team does not just read the latest standards. We actively participate in the development of industry standards through organizations like ISO and ASTM. This involvement gives us a unique perspective on where the industry is headed. When we help a client design a validation protocol, we are not just looking at the requirements of today. We are looking at the emerging trends and the feedback we hear from international regulatory bodies.
Following the most conservative path for validation can be expensive and time-consuming, but doing the bare minimum carries significant regulatory risks that can delay a product launch by months or even years. You need a process that is tailored to the unique needs of your device, with a risk-based data-driven approach.
By partnering with Cretex Medical | QTS, you gain access to a team that understands the interdependencies between cleaning, sterilization, and packaging. We provide the technical expertise and project management support necessary to navigate these technically demanding subjects. We ensure that your validation is not just a document that sits on a shelf, but a robust foundation for patient safety and regulatory success.
The landscape of cleaning validation will continue to change. However, with the right strategy and the right partner, you can ensure that your products meet the requirements of today and stay ahead of the requirements of tomorrow. Reach out to the team at Cretex Medical | QTS to learn how we can help future-proof your cleaning and sterilization processes.
Please visit our website for more information about Cretex Medical | QTS and our services.